Macrolide antibiotics: 25 years of use and the future treatment of common diseases
Use of Macrolide Antibiotic in treatment of common disease
Keywords:
Common diseases, diffuse panbronchiolitis, macrolide antibiotics, treatmentAbstract
The novel mechanism of action of macrolides was discovered when a significant improvement in the survival of patients with diffuse panbronchiolitis (DPB) receiving low dose of erythromycin was observed, and when their beneficial effect was found to be independent of their anti-microbial activity. Macrolides that are members of the 14- and 15-ring groups show beneficial effects against DPB but not those of the 16-ring groups. We could recognize these effects of macrolides because their administration was associated with reduced inflammatory response in chronic airway diseases including upper- and lowerrespiratory tract infections. The anti-inflammatory action of macrolides during infections by bacteria and virus with high virulence has been recently the focus of several studies. Thus, this interesting anti-inflammatory effect of macrolide is currently being assessed not only in the rare condition of DPB but also in common diseases such as viral airway infection. In this review, we will summarize the use of macrolides in common and rare diseases during the past 25 years.
References
Homma H, Yamanaka A, Tanimoto S, Tamura M, Chijimatsu Y, Kira S, et al. Diffuse panbronchiolitis: A disease of the transitional zone of the lung. Chest 1983;83:63-9.
Corne J. Diffuse panbronchiolitis: A new Japanese export? Lancet 1996;348:1465-6.
Yamanaka A, Saiki S, Tamura S, Saito K. Problems in chronic obstructive bronchial diseases, with special reference to diffuse panbronchiolitis. Naika 1969;23:442-51.
Isihara K, Iwasaki H, Katagami N, Sakamoto H, Lee E, Umeda B, et al. Characteristics in airwa resistance and uneven ventilation in patients with diffuse panbronchiolitis (DPB) and diffuse pulmonary emphysema. Kokyu Junkan 1984;32:627-32.
Nakata K. Revision of clinical guidelines for diffuse panbronchiolitis. In: Annual Report on the Study of Diffuse Lung Disease in 1998. Grant in Aid from the Ministry of Health and Welfare of Japan. Tokyo, 1999:109-111 (in Japanese).
Poletti V, Casoni G, Chilosi M, Zompatori M. Diffuse panbronchiolitis. Eur Respir J 2006;28:862-71.
Maeda M, Saiki S, Yamanaka A. Serial section analysis of the lesions in diffuse panbronchiolitis. Acta Pathol Jpn 1987;37:693-704.[PUBMED]
Iwata M, Colby TV, Kitaichi M. Diffuse panbronchiolitis: Diagnosis and distinction from various pulmonary diseases with centrilobular interstitial foam cell accumulations. Hum Pathol 1994;25:357-63.
Takizawa H, Tadokoro K, Miyoshi Y, Horiuchi T, Ohta K, Shoji S, et al. Serological characterization of cold agglutinin in patients with diffuse panbronchiolitis. Nihon Kyobu Shikkan Gakkai Zasshi 1986;24:257-63.
Kudoh S, Azuma A, Yamamoto M, Izumi T, Ando M. Improvement of survival in patients with diffuse panbronchiolitis treated with low-dose erythromycin. Am J Respir Crit Care Med 1998;157: 1829-32.
Hashiba M, Kondo K, Hamashima A, Koseki A, Miyamoto N, Murakami S, et al. Effect of macrolide therapy on microbes in nasal cavity and larynx of patients with chronic paranasal sinusitis. Jpn J Antibiot 2001;54 Suppl C:102-5.
Jaffe A, Francis J, Rosenthal M, Bush A. Long-term azithromycin may improve lung function in children with cystic fibrosis. Lancet 1998;351:420.
Saian L, Marshall BC, Mayer-Hamblett N, Burns JL, Quittner AL, Cibene DA, et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: A randomized controlled trial. JAMA 2003;290:1749-56.
Goswami, SK, Kivity S, Marom Z. Erythromycin inhibits respiratory glycoconjugate secretion from human airways in vitro. Am Rev Respir Dis 1990;141:72-8.
Tamaoki J, Takeyama K, Tagaya E, Konno K. Effect of clarithromycin on production and its rheological properties in chronic respiratory tract infections. Antimicrob Agents Chemother 1995; 39:1688-90.
Kadota J, Sakito O, Kohno S, Sawa H, Mukae H, Oda H, et al. A mechanism of erythromycin treatment in patients with diffuse panbronchiolitis. Am Rev Respir dis 1993;147:153-9.
Oishi K, Sonoda F, Kobayashi S, Iwagaki A, Nagatake T, Matsushima K, et al. Role of interleukin-8 (IL-8) and an inhibitory effect of erythromycin on IL-8 release in the airways of patients with chronic airway diseases. Infect Immun 1994;62:4145-52.
Tateda K, Standiford TJ, Pechere JC, Yamaguchi K. Regulatory effects of macrolides on bacterial virulence: Potential role as quorum-sensing inhibitors. Curr Pharm Des 2004;10:3055-65.
Tateda K, Ishii Y, Matsumoto T, Furuya N, Nagashima M, Matsunaga T, et al. Direct evidence for antipseudomonal activity of macrolides: Exposure-dependent bactericidal activity and inhibition of protein synthesis by erythromycin, clarithromycin, and azithromycin. Antimicrob Agents Chemother 1996;40:2271-75.
Tateda K, Comte R, Pechere JC, Köhler T, Yamaguchi K, Van Delden C. Azithromycin inhibits quorum sensing in Pseudomonas aeruginosa. Antimicrob Agents Chemother 2001;45:1930-3.
Hoffmann N, Lee B, Hentzer M, Rasmussen TB, Song Z, Johansen HK, et al. Azithromycin blocks quorum sensing and alginate polymer formation and increases the sensitivity to serum and stationary-growth-phase killing of Pseudomonas aeruginosa and attenuates chronic P. aeruginosa lung infection in Cfftr(-/-) mice. Antimicrob Agents Chemother 2007;51:3677-87.
Takizawa H, Desaki M, Ohtoshi T, Kawasaki S, Kohyama T, Sato M, et al. Erythromycin modulates IL-8 expression in normal and inflamed human bronchial epithelial cells. Am J Respir Crit Care Med 1997;156:266-71.
Desaki M, Takizawa H, Ohtoshi T, Kasama T, Kobayashi K, Sunazuka T, et al. Erythromycin suppresses nuclear factor-kappaB and activator protein-1 activation in human bronchial epithelial cells. Biochem Biophys Res Commun 2000;267:124-8.
Miyamoto D, Hasegawa S, Sriwilaijaroen N, Yingsakmongkon S, Hiramatsu H, Takahashi T, et al. Clarithromycin inhibits progeny virus production from human influenza virus-infected host cells. Biol Pharm Bull 2008;31:217-22.
Tsurita M, Kurokawa M, Imakita M, Fukuda Y, Watanabe Y, Shiraki K. Early augmentation of interleukin (IL-12) level in the airway of mice administered orally with clarithromycin or intranasally with IL-12 results in alleviation of influenza infection. J Pharmacol Exp Ther 2001;298:362-8.
Azuma A, Yamaya M, Kadota J, et al. The use of macrolides in the 2009 H1N1 virus infection outbreak: A survey of general practice in Japan. Respir Invest 2013;51:257-9.
Yamaya M, Azuma A, Tanaka H, Takizawa H, Chida K, Taguchi Y, et al. Inhibitory effects of macrolide antibiotics on the exacerbations and hospitalization in chronic obstructive pulmonary disease in Japan: A retrospective multicenter analysis. J Am Geriatr Soc 2008;56:1358-60.
Seemungal TA, Wilkinson TM, Hurst JR, Perera WR, Sapsford RJ, Wedzicha JA. Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. Am J Respir Crit Care Med 2008;178:1139-47.
Nakanishi Y, Kobayashi D, Asano Y, Sakurai T, Kashimura M, Okuyama S, et al. Clarithromycin prevents smoke-induced emphysema in mice. Am J Respir Crit Care Med 2009;179:271-8.
Albert RK, Connett J, Bailey WC, Casaburi R, Cooper JA Jr, Criner GJ, et al. COPD Clinical Research Network. Azithromycin for prevention of exacerbations of COPD. N Engl J Med 2011;365:689-98.
Downloads
Published
How to Cite
Issue
Section
Downloads
License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
